PharmaCyte Biotech, Inc. (PMCB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US71715X2036

Price
0.40 USD
Market cap
4.32 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-58.34 %
Return on assets (ROA)
-41.55 %

PharmaCyte Biotech, Inc. financials

Fiscal year20252026
Revenue0.00 USD0.00 USD
Operating income-4.38 m USD-6.85 m USD
EBIT30.66 m USD-19.42 m USD
Net income30.66 m USD-19.42 m USD
Diluted EPS – continuing operations3.19 USD-2.77 USD

Full history since 2002, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.